MRK
Merck & Co., Inc.
MRK
Merck & Co., Inc.
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the
Retail investors talked up five hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r/WallStreetBets, driven by retail hype, earnings, AI infrastructure momentum, and corporate news flow
It's not every day that a company already worth billions sees its shares nearly triple in a single trading session. Welcome to the world of biotech, because that's exactly what happened to Moderna Inc
As Moderna Inc. (NASDAQ: MRNA) stock spiked sharply on August 19, catalyzed by positive late-stage trial results for its personalized mRNA (messenger ribonucleic acid) cancer vaccine; $1,000 invested
BioNTech SE (NASDAQ:BNTX) stock is trading higher on Wednesday. Investors are probably reacting to Merck & Co Inc. (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) topline data from individualized cancer th
Merck & Co., Inc. surges to all-time highs after positive Phase 3 melanoma vaccine trial results with Moderna. MRK maintains a Buy rating, citing strong oncology growth, robust free cash flow, and tec
Moderna Inc (NASDAQ:MRNA) is powering up the Nasdaq this morning, last seen126.5% higher to trade at $142.61.
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript
SpaceX (SPCX) will deliver its first public earnings report, with focus on Starlink growth, Starship timeline, and capital spending. SPCX shares have fallen over 50% from peak and are 20% below the IP
Merck has extended Keytruda's lifecycle by launching subcutaneous Qlex, securing its exclusivity through 2039, and other extensions supporting market confidence. Recent regulatory approvals, promising
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on
Schwab U.S. Dividend Equity ETF remains a Buy for its blend of capital appreciation and dividend income. SCHD's top holdings, including ABT, UNH, and MRK, offer underappreciated catalysts and strong d
Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline a
Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reportedly neared an agreement to acquire a psychedelics company.
Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.